0001104659-26-027047
SEC filingCorvus Pharmaceuticals, Inc. reported a net loss of $15.3 million for the fiscal year ended December 31, 2025, a significant improvement from a net loss of $62.3 million in the prior year. This reduction was primarily driven by a $27.1 million gain from the change in fair value of warrant liability, which was reclassified to equity upon warrant exercise. The company incurred total operating expenses of $43.0 million, up from $27.5 million in 2024, with research and development expenses increasing to $33.7 million from $19.4 million due to expanded clinical trial activities for its lead product candidate, soquelitinib. Comprehensive loss was $14.9 million. As of December 31, 2025, the company had $56.8 million in cash, cash equivalents, and marketable securities, and total stockholders' equity of $61.2 million. The company is a clinical-stage biopharmaceutical company with no products approved for sale and has not generated any revenue.
Corvus Pharmaceuticals reported a net loss of $15.3 million for the fiscal year ended December 31, 2025, a substantial improvement from a net loss of $62.3 million in the prior year. This was primarily due to a $27.1 million gain from the change in fair value of warrant liability, which was reclassified to additional paid-in capital upon exercise of common stock warrants. Total operating expenses increased to $43.0 million from $27.5 million in 2024, driven by higher research and development costs. The company's loss from operations was $43.0 million, compared to $27.5 million in the prior year. Comprehensive loss was $14.9 million. The company has no products approved for sale and has not generated any revenue.
The company is a clinical-stage biopharmaceutical company and has not generated any revenue from product sales. Its operations are focused on the research and development of product candidates, including soquelitinib, ciforadenant, and mupadolimab. The document does not disclose any segment revenue or geographic revenue mix, as the company is pre-revenue and operates in a single segment for the development and commercialization of drugs targeting the immune system.
As a pre-revenue company, Corvus does not report gross profit or gross margin. The company's operating loss was $43.0 million for the year ended December 31, 2025, compared to $27.5 million in the prior year, reflecting increased investment in clinical development. Operating expenses consisted of $33.7 million in research and development (up from $19.4 million) and $9.3 million in general and administrative expenses (up from $8.2 million). The increase in R&D expenses is attributed to expanded clinical trial activities for soquelitinib. The company's net loss margin improved due to the non-cash gain from warrant liability revaluation.
Net cash used in operating activities was $32.8 million for the year ended December 31, 2025, compared to $25.4 million in the prior year. Net cash provided by financing activities was $36.4 million, primarily from proceeds from the exercise of common stock warrants ($35.7 million) and issuance of common stock and warrants. Net cash used in investing activities was $7.8 million, mainly for purchases of marketable securities. As of December 31, 2025, the company had $56.8 million in cash, cash equivalents, and marketable securities, total assets of $71.1 million, total liabilities of $9.9 million, and total stockholders' equity of $61.2 million. The company had an accumulated deficit of $412.3 million.
The company expects its existing capital resources, including proceeds from a January 2026 follow-on offering of approximately $189.4 million, to be sufficient to fund operations into the second quarter of 2028. However, it does not expect these resources to fund the completion of all ongoing and planned clinical trials and development programs through commercialization. Key development milestones include the ongoing Phase 3 trial for soquelitinib in relapsed peripheral T-cell lymphoma and a recently initiated Phase 2 trial for soquelitinib in atopic dermatitis. The company faces significant risks, including the need for additional financing, clinical trial failures, regulatory delays, and intense competition. It relies on third parties for manufacturing and clinical trials and has no sales, marketing, or distribution capabilities.